Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Current guidelines suggest limiting diagnostic testing for chronic spontaneous urticaria when no clear cause is suspected, though biomarkers and biopsies are emerging as tools to predict treatment ...

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company’s press release.

Addressing postmarketing reports of psoriasis in patients treated with dupilumab for AD, researchers conducted a population-based retrospective cohort study of 214,430 adults with AD from the ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, breaks down how to communicate the value of dupilumab using patient-centered language and sports metaphors to patients.

In the trial, Dupixent ® (dupilumab) outperformed Xolair ® (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints.